&w=3840&q=100)
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
GSK Pharma share price: GlaxoSmithKline Pharmaceuticals (GSK Pharma) shares were in demand on Wednesday, May 14, 2025, with the scrip rallying up to 8.46 per cent to hit an intraday high of Rs 3,026.20 per share.
At 11:10 PM, however, the GSK Pharma shares were off highs, and were trading 4.18 per cent higher at Rs 906.85 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 81,460.24 level.
What sparked the up move in GSK Pharma share price?
The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 (Q4FY25) results.
For the quarter ended March 31, 2025 (Q4FY25), GSK Pharma reported a revenue of Rs 966 crore, a like-to-like growth of 6 per cent. The profit after tax (PAT) for the quarter stood at Rs 260 crore.
Meanwhile, the company reported full year revenue of Rs 3,723 crore, a growth of 9 per cent from FY24. The PAT before exceptional items (bei) zoomed 32 per cent to Rs 915 crore, and Ebitda margins expanded 500 basis points (bps) to 31.4 per cent.
Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.'
'We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,' Akshikar added.
Furthermore, the company revealed that it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer.
GSK Pharma dividend, record date
The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended March 31, 2025, subject to approval of members at 100th Annual General Meeting (AGM).
The Company has fixed Friday, May 30, 2025, as the 'Record Date' for determining entitlement of members to final dividend for FY25.
About GSK Pharma
GlaxoSmithKline (GSK) Pharmaceuticals is a global healthcare company specialising in vaccines, specialty medicines, and general medicines.
It operates under GSK plc, a British multinational pharmaceutical corporation headquartered in London.
GSK India, a subsidiary of GSK plc, is a biopharmaceutical company engaged in the development and marketing of vaccines and medicines, with a strong focus on infectious diseases, HIV, oncology, and immunology.\
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
UP CM directs officials to take action against fake, shell companies
Uttar Pradesh Chief Minister Yogi Adityanath on Saturday directed officials to take action against shell companies to stop the attempts to misuse the facilities meant for genuine traders. While conducting a high-level review of the State Tax Department, the CM directed officials to ensure transparency in tax collection and adopt a policy of technological efficiency and strict enforcement. "Tax evasion is a national crime that negatively impacts development plans and welfare schemes," he said. Stressing that the Goods and Services Tax (GST) is a consumer-based tax system, he noted that areas with higher population density are naturally expected to generate more tax revenue. He instructed officials to develop special strategies for zones where tax collection is below average. Adityanath directed that information on suspicious firms registered under Central GST (CGST) be shared with the Centre for cancellation of their registration. For firms under State GST (SGST), he ordered in-depth departmental investigations, and if irregularities are found, their registration should be canceled and FIRs lodged. The CM emphasised the need for on-site inspection of all newly registered firms, stating "fake companies should not be allowed to obstruct the rights of honest taxpayers. CM Adityanath said that such acts are an attempt to misuse the facilities meant for genuine traders, which is unforgivable. Such inspections are essential to ensure that genuine businesses can operate fairly and without interference," he said. During the meeting, officials informed the CM that Rs 18,161.59 crore in GST and VAT had been collected during April and May against the financial year 2025-26 target of Rs 1,75,725 crore.
Time of India
an hour ago
- Time of India
Circular rail network on Bengaluru's outskirts to cost Rs 81,000 crore
Bengaluru: The proposed Circular Rail Link Project on Bengaluru's outskirts requires an investment of Rs 81,000 crore and acquisition of 2,500 acres of land. Spanning 287km, the double-line circular network will connect Nidavanda, Doddaballapur, Devanahalli, Malur, Heelalige, Solur and other peripheral towns. It aims to decongest rail traffic in the city's core areas and cater to residents on the outskirts and nearby districts by enabling more suburban rail services. On Saturday, minister of state for railways V Somanna held a meeting with MPs from Bengaluru and adjoining districts to discuss the project. The railway board sanctioned a final location survey (FLS), which is currently being conducted in phases. The minister said the central govt will fund the entire project. "This is a long-term initiative meant to benefit Bengaluru over the next 50 years," he said. The actual land requirement and cost will be finalised after the detailed project report (DPR) is ready. Completing the FLS is expected to take several months. Camelaram, Panathur works Bangalore Central MP PC Mohan submitted a requisition to Somanna, urging South Western Railway (SWR) to coordinate with BBMP to expedite pending RoB and RuB works at Carmelaram and Panathur. He noted that only 35% of the Carmelaram RoB is complete, causing prolonged closure of Carmelaram-Gunjur Road and affecting commuters. Similarly, the Panathur RuB is stalled due to BBMP's delay in acquiring land needed for the approach road and drainage. Need superfast train to Mumbai: Mohan Mohan called for a superfast train between Bengaluru and Mumbai, pointing out that the current Udyan Express takes over 20 hours. Despite repeated public requests, the railway board hasn't approved a faster service, he said. On the redevelopment of KSR Bengaluru City Railway Station, the MP said the proposal is pending with the railway board. He urged Somanna to initiate a feasibility study for a rapid rail transit system (RRTS) on key corridors such as Bengaluru-Tumakuru, Bengaluru-Ramanagara, Bengaluru-Mandya-Mysuru and Bengaluru-Kolar.
Time of India
an hour ago
- Time of India
Ayurvedic & herbal products manufacturers in Indore ramp up production as Covid cases increase
Indore: As Covid-19 cases are witnessing an uptick, manufacturers of Ayurvedic and herbal products in Indore have ramped up their production capacities, anticipating a surge in demand for immunity-boosting products. Usually, summers remain the lean season for immunity booster syrups and tablets, but the resurgence of Covid-19 cases led to a jump in enquiries, prompting many units to prepare for increased production ahead of their usual season. Ayush Nirmata Sangh secretary Ashish Dubey said, "We are anticipating a surge in demand for immunity boosters as cases of Covid-19 again started to increase. Many units started preparations and are gradually increasing production." Another manufacturer owner of a local Ayurvedic firm Ravi Kumar said, "We saw an increase in enquiries for our immunity products. To meet this demand, we are expanding our operations to ensure we can deliver quality products to our customers promptly. Also, monsoon and winters are main demand period of Ayurvedic products when demand rises." Industry insiders noted that if the consumption of these products would not meet their expectations, they would still find a market during the monsoon and winter seasons when the demand for syrups and immunity boosters typically spikes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo Ayurvedic products produced in Indore are distributed across various states in India, including Delhi, Punjab, Maharashtra, Uttar Pradesh, and Uttarakhand, according to local manufacturers. In response to the heightened demand, many manufacturing units are transitioning to automatic production processes, while others are opting for semi-automatic configurations to enhance efficiency. Indore is home to around 240 Ayurvedic medicine manufacturing units, with the total market size exceeding an impressive Rs 1000 crore, as reported by Ayush Nirmata Sangh.
